Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy

Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines

(2016) Jinho Park et al.   ADVANCED DRUG DELIVERY REVIEWS

Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey

(2016) Can Sarisozen et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Current attempts to implement siRNA-based RNAi in leukemia models

(2016) Hasan Uludağ et al.   DRUG DISCOVERY TODAY

Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles

(2016) Tsukasa Sugo et al.   JOURNAL OF CONTROLLED RELEASE

An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing

(2016) Konrad Bienk et al.   JOURNAL OF CONTROLLED RELEASE

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

(2015) Thomas Dörner et al.   AUTOIMMUNITY REVIEWS

Improved assembly of bispecific antibodies from knob and hole half-antibodies

(2015) Ambrose Jon Williams et al.   BIOTECHNOLOGY PROGRESS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

(2015) Denise Niewerth et al.   DRUG RESISTANCE UPDATES

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

(2015) Jingjing Wu et al.   Journal of Hematology & Oncology

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation

(2015) E. Erica Hong et al.   MOLECULAR PHARMACEUTICS

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

(2015) John E. Janik et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma

(2015) Amitkumar Mehta et al.   Current Oncology Reports

Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia

(2015) Breanne Landry et al.   Molecular Therapy-Nucleic Acids

Are BiTEs the “missing link” in cancer therapy?

(2015) Carter M Suryadevara et al.   OncoImmunology

Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies

(2015) Richard G. Langley et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas

(2014) A. de Masson et al.   BRITISH JOURNAL OF DERMATOLOGY

Current status of antibody therapy in ALL

(2014) Jing Ai et al.   BRITISH JOURNAL OF HAEMATOLOGY

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch

(2014) Farrukh T. Awan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers

(2014) Min Kyung Joo et al.   JOURNAL OF CONTROLLED RELEASE

Antibodies to watch in 2015

(2014) Janice M Reichert   mAbs

A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia

(2014) Zhaogang Yang et al.   Nanoscale

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

(2014) Jens Niewoehner et al.   NEURON

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates

(2014) Trinna L. Cuellar et al.   NUCLEIC ACIDS RESEARCH

Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

(2014) Muneera Al-Hussaini et al.   Expert Review of Hematology

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

(2014) A Ehninger et al.   Blood Cancer Journal

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Molecular Parameters of siRNA–Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery

(2013) Alexander H. van Asbeck et al.   ACS Nano

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study

(2013) Howard A. Liebman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

(2013) Harry P. Erba et al.   INVESTIGATIONAL NEW DRUGS

Comparative core fucosylation analysis of some major therapeutic antibodyN-glycans by direct infusion ESI-MS and CE-LIF detection

(2013) Yueju Wang et al.   JOURNAL OF SEPARATION SCIENCE

Site-Specific Antibody–Polymer Conjugates for siRNA Delivery

(2013) Hua Lu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

(2013) Wei He et al.   MOLECULAR THERAPY

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Addition of Rituximab to High-Dose Methotrexate-Based Chemotherapy Improves Survival of Adults with Burkitt Lymphoma/Leukemia

(2012) Dino Dujmovic et al.   ACTA HAEMATOLOGICA

Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties

(2012) Edmund A. Rossi et al.   BIOCONJUGATE CHEMISTRY

Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates

(2012) Karen J. Vincent et al.   Biotechnology Journal

Toward victory in adult ALL: blinatumomab joins in

(2012) R. Bassan   BLOOD

Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake

(2012) Boris Gorovits et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Critical Issues in Delivery of RNAi Therapeutics In Vivo

(2012) Stephanie Rivera et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations

(2012) Tim M Illidge   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody–drug conjugates – a perfect synergy

(2012) John R Adair et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

(2012) M. A. Sekeres et al.   HAEMATOLOGICA

The interactions of therapeutic antibodies with Fc receptors

(2012) Marcello Albanesi et al.   IMMUNOLOGY LETTERS

Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex

(2012) Nianxi Zhao et al.   JOURNAL OF CONTROLLED RELEASE

A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments

(2012) S.L. Malcolm et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

A strategy for risk mitigation of antibodies with fast clearance

(2012) Isidro Hötzel et al.   mAbs

Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes

(2012) Chenguang Zhou et al.   Nanomedicine-Nanotechnology Biology and Medicine

Antibody Therapy for Acute Lymphoblastic Leukemia

(2012) Craig A. Portell et al.   Current Hematologic Malignancy Reports

Targeting Chronic Myeloid Leukemia Stem Cells

(2012) Ross Kinstrie et al.   Current Hematologic Malignancy Reports

Humanized Lewis-Y Specific Antibody Based Delivery ofSTAT3siRNA

(2011) Yuelong Ma et al.   ACS Chemical Biology

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

(2011) E. Park et al.   BLOOD

Chemoimmunotherapy in acute lymphoblastic leukemia

(2011) Dieter Hoelzer et al.   BLOOD REVIEWS

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

(2011) Jorge Cortes et al.   CANCER

Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies

(2011) Joshua M. Donaldson et al.   CANCER BIOLOGY & THERAPY

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response

(2011) J M Brandwein et al.   LEUKEMIA

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

(2011) Mark C. Lanasa et al.   LEUKEMIA & LYMPHOMA

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

(2011) Daniela Bumbaca et al.   mAbs

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

(2011) Ingo Schubert et al.   mAbs

Too many roads not taken

(2011) Aled M. Edwards et al.   NATURE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML

(2010) Bing Z. Carter et al.   APOPTOSIS

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

(2010) R. B. Walter et al.   BLOOD

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

(2010) Francesco D’Amore et al.   BRITISH JOURNAL OF HAEMATOLOGY

β-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cells

(2010) Jenny Yeung et al.   CANCER CELL

Origin of Chromosomal Translocations in Lymphoid Cancer

(2010) André Nussenzweig et al.   CELL

Ofatumumab, a human anti-CD20 monoclonal antibody

(2010) Anders Österborg   EXPERT OPINION ON BIOLOGICAL THERAPY

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems

(2010) Miriam Rothdiener et al.   JOURNAL OF CONTROLLED RELEASE

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

(2010) P. Kletting et al.   JOURNAL OF NUCLEAR MEDICINE

Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

(2010) May Kung Sutherland et al.   mAbs

Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide

(2010) Puja Sapra et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

(2009) Azra Raza et al.   LEUKEMIA & LYMPHOMA

Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion protein

(2009) Akiko Eguchi et al.   NATURE BIOTECHNOLOGY

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

(2009) Aimee L. Jackson et al.   NATURE REVIEWS DRUG DISCOVERY

Small silencing RNAs: an expanding universe

(2009) Megha Ghildiyal et al.   NATURE REVIEWS GENETICS

In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(–PEG)/siRNA complexes

(2009) Anastasia Malek et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Off-target activity of TNF-α inhibitors characterized by protein biochips

(2008) Oliver Feyen et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Chromosomal translocations in cancer

(2008) Mridula Nambiar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

(2008) Roberto Stasi   EXPERT OPINION ON BIOLOGICAL THERAPY

CD22: an inhibitory enigma

(2008) Jennifer A. Walker et al.   IMMUNOLOGY

Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2

(2008) Xiaojuan Yang et al.   MOLECULAR PHARMACEUTICS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY